(Total Views: 515)
Posted On: 03/08/2021 2:13:55 AM
Post# of 148903
Re: ToTheMoonAlice #81849
ToTheMoon,
The big deal is that the p value reflects the probability that the results are real and not due to chance. P<0.05 is arbitrary, but indicates 95% certainty that the observed benefit is real.
Additionally, the 24% mortality reduction was in the critical intubated subset of the entire 384 patient population.
This being a pandemic with thousands in the US dying daily, this would seem the appropriate use for EUA.
These results are far to weak for approval, but good guidance for another trial for approval. Essentially this trial, with the range of included patients, is more the phase 2b part of its designation than phase 3.
Another delay sucks, but this is more evidence that the drug works. Investors holding will be ok. Critical patients denied Leronlimab, maybe not.
The big deal is that the p value reflects the probability that the results are real and not due to chance. P<0.05 is arbitrary, but indicates 95% certainty that the observed benefit is real.
Additionally, the 24% mortality reduction was in the critical intubated subset of the entire 384 patient population.
This being a pandemic with thousands in the US dying daily, this would seem the appropriate use for EUA.
These results are far to weak for approval, but good guidance for another trial for approval. Essentially this trial, with the range of included patients, is more the phase 2b part of its designation than phase 3.
Another delay sucks, but this is more evidence that the drug works. Investors holding will be ok. Critical patients denied Leronlimab, maybe not.
(5)
(1)Scroll down for more posts ▼
